Analysis of 21 oncology unicorns: US-based firms dominate, none from Europe on the CB Insights list
A study of 21 oncology companies valued above $1 billion finds the list US-dominated and without European entries; the authors link this to a translation gap, not to science.
A strategic analysis available via doi.org examines 21 oncology unicorns, privately held companies valued above $1 billion, drawn from the CB Insights database. The authors report that this landscape is dominated by the United States and that no European entity appears on the list springer.com
doi.orgspringer.comOpen source ↗. The combined valuation of the 21 companies exceeds $50 billion.
Funding pattern behind the list
The authors found that at least $200 million of cumulative investment is required to build an oncology unicorn. They describe this as a quantitative measure of the financing gap. According to the analysis, the US ecosystem rests on deep pools of institutional capital, a culture of high-risk investment consortia and scalable, technology-forward business models.
The investor base is dominated by US institutional players that form large consortia, and a small number of individual super-investors took part in several of these companies. The main business areas attracting investment are pharmaceutical drug research services, blood and genetic testing, and proprietary pharmaceutical products.
The translation gap in Europe
The authors state that the absence of European companies is not a lack of scientific excellence. They cite institutions such as the Max Planck Society as world leaders in basic research. In their view the deficit lies in turning that research into high-growth companies springer.com
doi.orgspringer.comOpen source ↗.
They also argue that the US advantage is not simply more money. It is an ecosystem in which capital, expertise, risk-taking, regulatory pathways and potential exits are aligned around translation. As an illustration, a theoretical 2% share of the combined value of the 21 companies would create a $1 billion fund for cancer research. The authors propose a roadmap with five interconnected priorities and add that reimbursement, health technology assessment and patient access belong to the same ecosystem.
The authors note the limits of the work. It relies on a single database and a specific definition of oncology unicorns. It identifies patterns and correlations but cannot establish direct causation between investment strategies and a company's success. Further research on early-stage startups in the US, China and Europe is proposed to clarify the cause.
